Pharmaceuticals and Biotech
10 Jan 2020  |  Asia Pacific
Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry
With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...
USD 9,000.00 save 10 %
28 Apr 2020  |  Global
Empowering Medical, Academic and Industrial Communities Through Expert Advice Across Multiple Scientific Disciplines
Overall Impact of Breakthrough Innovations in Gut Microbial Health Covered in this Research - Microbiome expertise: Meeting translational research needs from medical, academic and industrial communities through deep diving know-how and expertise across multiple scientific platforms - Nutrition and therapeutic fields: Enabling precision medicine an...
05 May 2020  |  North America
Benchmarking Future Growth Potential
Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...
07 Jul 2020  |  Global
Emerging Chimeric Antigen Receptor (CAR) T-cell Therapy Platforms
This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.
21 Aug 2020  |  Global
Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities
In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new...
23 Oct 2020  |  Global
Supply Chain Optimization and Decentralized Manufacturing to Expand the Contract Cell and Gene Therapy Manufacturing Market, 2020–2026
Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization will Create New Growth Opportunities
The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater reach and a...
24 Jul 2020  |  North America
Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies
With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies,...
05 Feb 2021  |  North America
Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market
Early-stage R&D and Commercial Applications Fuel the Growth Pipeline
The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...
12 Aug 2020  |  North America
New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025
AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities
Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...
23 Oct 2020  |  North America
Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities
In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market ...